NEW YORK (TheStreet) -- CHANGE IN RATINGS
Actuate (BIRT) was downgraded to hold at TheStreet Ratings.
Catamaran (CTRX) was downgraded at ISI Group to neutral from buy. Twelve-month price target is $50. Company's profit outlook is going through a transition period, ISI Group said.
Endologix (ELGX) was downgraded at Oppenheimer to outperform from perform. Twelve-month price target is $16. Domestic business is facing increased competition, Oppenheimer said.
Eaton Vance (EV) was upgraded at Sterne Agee to buy from neutral. Valuation call, as headwinds could be nearing a bottom, Sterne Agee said.
Intermune (ITMN) was downgraded at Credit Suisse to neutral from outperform. Valuation call, based on a 12-month price target of $33, Credit Suisse said.
M/I Homes (MHO) was downgraded to hold at TheStreet Ratings.
Mylan (MYL) was downgraded at Needham to hold from buy. Valuation call, as the stock is up 36% year to date, Needham said.
NCI Building Systems (NCS) was initiated at UBS with a buy rating. Strong leverage to a nonresidential construction recovery, UBS said. Twelve-month price target is $21. Buy rating.
State Street (STT) was downgraded at RBC Capital to sector perform from outperform. Twelve-month price target is $68. Estimates were also cut, given lower sales and higher expected costs, RBC Capital said.
Westlake (WLK) was upgraded at J.P. Morgan to overweight from neutral.
American Airlines ( AAL) price target was raised at UBS. Large cost-savings plans to come, UBS said. Twelve-month price target is $37. Neutral rating.
Alkermes (ALKS) price target was raised at UBS. Driven by manufacturing and royalty revenue, UBS said. Twelve-month price target is $53. Neutral rating.
Deckers (DECK) estimates, price target were raised at Credit Suisse. Twelve-month price target is now $61. Estimates were also increased, given higher demand across the board, Credit Suisse said. Underperform rating.
Foster Wheeler (FWLT) price target, EPS estimates were increased at UBS. E&C bookings are healthy, and Power bookings are better than expected, UBS said. Twelve-month price target is $33. Neutral rating.